← Markets

Enliven Therapeutics, Inc.

ELVN · NASDAQ

Market closed$53.20$2.34 (+4.60%)After hours $53.20 · 0.00%

Key statistics

Previous close$50.86
Open$49.80
Day high$54.08
Day low$49.56
52-week high$54.10
52-week low$14.79
Market cap3.80B
Volume814.67K
Average volume1.30M
P/E ratio-31.86
Forward P/E—
EPS-1.67
Dividend yield0.00%

Market context

Why it moved

Enliven Therapeutics (ELVN) surged today as a technical breakout with no remaining resistance levels above the current price drove strong bullish sentiment, fueling continued momentum following the stock's impressive year-to-date gains.

SubstackMarketbeatFctulsaBulldawgillustratedStockoscope

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026Enliven Therapeutics surged, brushing up against its 52-week high of $54.10, after investors responded enthusiastically to positive Phase 1 data from its ENABLE trial for lead oncology candidate ELVN-001 in chronic myeloid leukemia. The upbeat results fueled analyst price target increases — H.C. Wainwright raised its target to $65 and Jones Trading lifted its to $70 — while the company's recently completed $460 million public offering bolsters its runway toward a planned Phase 3 trial. The move outpaced a broadly weaker healthcare sector backdrop, with the sector ETF (XLV) closing lower amid broader market turbulence tied to AI concerns and U.S.-Iran tensions.

4.6009

July 17, 2026Enliven Therapeutics shares fell sharply, pulling back from a 52-week high of $52.47 reached just the prior session, as broader tech and growth stock pressure weighed on high-valuation biotech names. The stock had surged over 236% year-to-date heading into the session, fueled by positive Phase 1 ENABLE trial data and analyst upgrades from H.C. Wainwright (Buy, $65 PT) and Jones Trading (Buy, $70 PT). Thursday's selloff in AI-linked and richly valued growth stocks — with the Nasdaq declining ~0.8% — appeared to drag Enliven lower alongside peers, even as the healthcare sector (XLV) held relatively firm.

-4.3266

July 16, 2026Enliven Therapeutics shares closed up nearly 3%, touching a new 52-week high, buoyed by strong analyst conviction and momentum from its Phase 1 ENABLE trial data. H.C. Wainwright raised its price target to $65 and Jones Trading lifted its target to $70 (from $45), both maintaining Buy ratings following the positive Phase 1 update. The stock has surged over 236% year-to-date, supported by an upsized $460 million public offering and a growing pipeline narrative, with sentiment further aided by UBS upgrading its broader healthcare sector outlook and biotech M&A tailwinds.

2.7644

July 10, 2026Enliven Therapeutics closed down roughly 2% as the stock pulled back from near its 52-week high, despite a bullish analyst catalyst: H.C. Wainwright raised its price target to $65 from $56 and boosted its probability of approval for ELVN-001 to 70%, citing strong updated Phase 1 ENABLE trial data showing a 61% overall major molecular response rate in heavily pretreated chronic myeloid leukemia patients. The retreat may reflect profit-taking after a remarkable ~230% year-to-date run, a valuation debate flagged by some analysts, and a recent director share sale under a pre-arranged 10b5-1 plan — even as the broader biotech sector continues to attract momentum-driven investor interest.

-2.0889

July 10, 2026Enliven Therapeutics rose nearly 3%, brushing up against its 52-week high, as H.C. Wainwright raised its price target to $65 (from $56) and Jones Trading lifted its target to $70 — both citing strong Phase 1 ENABLE trial data for ELVN-001 in chronic myeloid leukemia presented at the EHA meeting in Stockholm. The 61% major molecular response rate at 24 weeks drove Wainwright to increase its probability of approval to 70% from 55%, reinforcing the Strong Buy consensus across analysts. The move comes amid a bullish broader biotech backdrop, with Jim Cramer calling the sector "the hottest group in the market" on anticipated M&A activity under a more favorable regulatory environment.

2.7165

July 8, 2026Enliven Therapeutics closed essentially unchanged, holding near its 52-week high of $52.39, as the broader market faced a risk-off session driven by Trump declaring the U.S.-Iran peace deal 'over,' sending oil surging 5%+ and pressuring equities broadly. The healthcare sector demonstrated relative resilience — XLV posted its second consecutive week of market-leading gains — buoyed by Jim Cramer calling biotech 'the hottest group in the market' and predicting an M&A wave under a more favorable FDA. A director at Enliven, Lori Anne Kunkel, sold 10,000 shares on July 6 under a pre-arranged 10b5-1 plan for ~$505K, a routine but notable filing as the stock trades close to its annual peak.

-0.2357

July 8, 2026Enliven Therapeutics gained nearly 2%, closing near its 52-week high of $52.39, as biotech sentiment surged amid Jim Cramer calling the sector 'the hottest group in the market' and predicting a wave of M&A deals following a more favorable FDA regulatory environment. The stock, a CML-focused clinical-stage company that has already drawn analyst price targets as high as $80 from Guggenheim, is seen as a potential acquisition candidate in an active dealmaking landscape where Eli Lilly and Gilead are aggressively pursuing oncology assets.

1.8196

July 6, 2026Enliven Therapeutics closed modestly higher, with the healthcare sector providing a supportive backdrop as XLV neared its 52-week high amid a broader health care winning streak. Investor attention remains squarely on valuation concerns following a 220%+ year-to-date surge, with analysts flagging the stock as potentially overvalued at a P/B of 7.7x versus the industry average of 2.4x. The core debate for investors centers on whether the ongoing ENABLE-2 Phase 3 trial for ELVN-001, alongside the pipeline HER2 inhibitor ELVN-002, can deliver enough clinical progress to justify the premium, especially amid recent insider and major shareholder selling.

0.3814

Stock Titan · July 17, 2026Enliven Therapeutics (ELVN) investor Helen Collins plans sale of 15,000 sharesInvesting.com · July 15, 2026Enliven Therapeutics stock hits 52-week high at 52.47 USDMoomoo · July 9, 2026H.C. Wainwright Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $64Simply Wall Street · July 9, 2026Enliven Therapeutics (ELVN) Fell Out Of Russell Indexes, But Is The Valuation Already Rich?Wilson Sonsini · June 17, 2026Wilson Sonsini Advises Enliven Therapeutics on $460 Million Follow-On OfferingStock Titan · June 11, 2026CML drug ELVN-001 hits 61% major molecular response as FDA agrees on Phase 3STAT · June 11, 2026Enliven Therapeutics' leukemia drug shows promise in new study | STATPR Newswire · May 7, 2026Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
Mt Newswire · July 8, 2026Enliven Therapeutics Insider Sold Shares Worth $504,903, According to a Recent SEC Filing
Benzinga · July 1, 2026Stifel Maintains Buy on Enliven Therapeutics, Raises Price Target to $80
Benzinga · June 29, 2026Jones Trading Maintains Buy on Enliven Therapeutics, Raises Price Target to $70
Mt Newswire · June 22, 2026Enliven Therapeutics Insider Sold Shares Worth $263,577, According to a Recent SEC Filing
Mt Newswire · June 12, 2026Enliven Therapeutics Prices $400 Million Public Offering
Mt Newswire · June 11, 2026Enliven Therapeutics Launches $250 Million Public Offering
Benzinga · June 11, 2026Enliven Therapeutics Presents Data From The Phase 1 Enable Clinical Trial Evaluating ELVN-001 In Patients With Previously Treated Chronic Myeloid Leukemia; Notes Encouraging Efficacy Data By 24 Weeks
Mt Newswire · June 9, 2026Enliven Therapeutics Insider Sold Shares Worth $345,351, According to a Recent SEC Filing

Peers

S&P 500SPX · $7,457.69-1.01%Summit Therapeutics Inc.SMMT · $13.81+0.36%ANI Pharmaceuticals, Inc.ANIP · $79.20-3.32%Structure Therapeutics Inc.GPCR · $48.48+5.32%Amphastar Pharmaceuticals, Inc.AMPH · $19.75-0.58%Liquidia CorporationLQDA · $79.94+6.20%Arrowhead Pharmaceuticals, Inc.ARWR · $74.30+4.10%Elanco Animal Health IncorporatedELAN · $25.83-0.46%Replimune Group, Inc.REPL · $10.23+7.46%Zentalis Pharmaceuticals, Inc.ZNTL · $5.11+11.82%Intensity Therapeutics, Inc.INTS · $4.75-3.06%Lantern Pharma Inc.LTRN · $2.87-1.37%